Skye Bioscience, Inc. Common Stock
SKYEStock
$0.63−83.79%52W
Market Cap$21.30M
P/E—
Div yield—
Beta2.98
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-54.86%
Price vs S&P 500 (4W)-16.23%
VGM Score19.28
Market Capitalization$21.30M
Earnings Surprise History
Q1 26-0.32est. -0.32
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.07
4.07
4.07
4.07
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SKYESkye Bioscience, Inc. Common Stock | — | — | F | $0.63 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Skye Bioscience is a San Diego-based pharmaceutical company developing CB1 receptor-targeted therapies for metabolic and inflammatory disorders. Lead candidates in Phase 2 are nimacimab for obesity and SBI-100 Ophthalmic Emulsion for glaucoma and ocular hypertension. The platform also targets fibrotic and neurodegenerative diseases.